Exactly right -- we need to save a whole bunch of
Post# of 148326
Just think how much they spend advertising drugs like Humira, to get people to ask their doctors for prescriptions. If CYDY just breaks even on the Philippines, and then it sells millions of doses for a fair price -- it will be a bargain for the company.
And if they can actually turn a profit without PRICING THE DRUG OUT OF THE MARKET, all the better. People are paying up for Remdesivir because it has U.S. EUA. Leronlimab doesn't. Who's going to pay much for a drug that they are not sure is efficacious? I say, get what the traffic will bear, be it a lowball price -- and then you have pricing power later on. Not that I think the company should gouge for this, the way they are gouging for Remdesivir.